Epizyme Reports Positive Updated Interim Data from Phase 2 Study of Tazemetostat in Patients With Relapsed or Refractory Follicular Lymphoma at the Congress of the European Hematology Asso...
Epizyme, Inc. (EPZM)
Last epizyme, inc. earnings: 2/24 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
epizyme.com
Company Research
Source: GlobeNewswire
Consistently High Responses in Patients with an EZH2 Activating MutationDurable Clinical Responses and Progression-Free Survival Observed in Patients With or Without an EZH2 Activating MutationCompany to Host Investor Conference Call Today at 8:30 a.m. EDT CAMBRIDGE, Mass., June 15, 2018 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage company developing novel epigenetic therapies, announced positive interim data from an ongoing Phase 2 study of its lead candidate tazemetostat, a potent, selective, orally available EZH2 inhibitor, as a monotherapy for patients with relapsed or refractory follicular lymphoma (FL). The data, presented today at the 23rd Congress of the European Hematology Association (EHA) in Stockholm, show that tazemetostat demonstrated meaningful clinical activity and was generally well tolerated in these heavily pre-treated patients. Interim data as of May 1, 2018 included 82 evaluable patients across two cohorts, prospectively assigned by EZ
Show less
Read more
Impact Snapshot
Event Time:
EPZM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EPZM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EPZM alerts
High impacting Epizyme, Inc. news events
Weekly update
A roundup of the hottest topics